Merck's Fosamax May Boost Cancer Risk: FDA Official

Law360, New York (January 5, 2009, 12:00 AM EST) -- In the latest blow to Merck & Co. Inc. over Fosamax, a U.S. Food and Drug Administration official has said the popular osteoporosis treatment and other similar drugs may increase the risk of developing esophageal cancer.

Diane Wysowski of the FDA's division of drug risk assessment said in a letter published Thursday in the New England Journal of Medicine that the potential links should be explored between bone disease medications known as bisphosphonate drugs, such as Fosamax, and cancer, Reuters reported.

Between the time of the...
To view the full article, register now.